Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025 along with the Auditors Report for the said period.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.6 pts less than Nifty Microcap 250 and 10.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Sciences Limited announced audited consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditor Deloitte Haskins & Sells LLP issuing an unmodified opinion. Consolidated revenue from operations for FY25 was Rs. 1,283.76 Cr, marginally down from Rs. 1,288.92 Cr in FY24, while Q4 FY25 revenue fell to Rs. 273.01 Cr from Rs. 299.43 Cr in Q4 FY24. The company swung to a slim profit of Rs. 0.54 Cr in FY25 from a steep loss of Rs. (566.96) Cr in FY24, which included a one-time exceptional item loss of Rs. 190.17 Cr. Q4 FY25 itself posted a loss of Rs. (2.10) Cr, but far better than Q4 FY24's loss of Rs. (255.45) Cr. The board also approved allotment of 1,00,000 ESOP shares at Rs. 252 each, appointed Grant Thornton Bharat LLP as internal auditor for FY26, appointed a new secretarial auditor for a 5-year term, and replaced the company secretary.
Shareholders see a sharp headline turnaround from last year's huge loss, but most of the recovery simply reflects the absence of FY24's Rs. 190 Cr exceptional charge — underlying profitability remains very thin and Q4 was still in the red, signalling continued operational pressure despite year-on-year improvement.